27 - 29 May, 2026
Congress CenterBasel SwitzerlandDr. Justin Killebrew, PhDVice President of Biology at Bonum TherapeuticsSpeaker
Profile
Dr. Justin Killebrew is Vice President of Biology at Bonum Therapeutics, bringing over 15 years of experience in oncology and immunology innovation. He joined Good Therapeutics in 2018 and transitioned to Bonum following Good’s acquisition by Roche in 2022. Previously, he led discovery biology at Silverback Therapeutics and advanced immunotherapy programs at Bristol-Myers Squibb. Dr. Killebrew holds a Ph.D. in Immunology from the University of Washington.
Agenda Sessions
cLAG3-IL2 (BON-101): A Conditionally Active Therapeutic using Dual-Binding Antibody Technology
, 16:45View Session